Pharmacokinetic/pharmacodynamic Issues for Optimizing Treatment with Beta-lactams of Gram-negative Infections in Critically Ill Orthotopic Liver Transplant Recipients: a Comprehensive Review

Overview

Journal Front Antibiot

Date 2025 Jan 16

PMID 39816245

Authors

Milo Gatti

Federico Pea

Affiliations

Soon will be listed here.

Abstract

Orthotopic liver transplant (OLT) represents the standard of care for managing patients affected by end-stage and life-threatening liver diseases. Although a significant improvement in surgical techniques, immunosuppressant regimens, and prompt identification of early post-transplant complications resulted in better clinical outcome and survival in OLT recipients, the occurrence of early bacterial infections still represents a remarkable cause of morbidity and mortality. In this scenario, beta-lactams are the most frequent antimicrobials used in critical OLT recipients. The aim of this narrative review was to provide a comprehensive overview of the pathophysiological issues potentially affecting the pharmacokinetics of beta-lactams and to identify potential strategies for maximizing the likelihood of attaining adequate pharmacokinetic/pharmacodynamic (PK/PD) targets of beta-lactams in critically ill OLT recipients. A literature search was carried out on PubMed-MEDLINE database (until 31 March 2024) in order to retrieve clinical trials, real-world observational evidence, and/or case series/reports evaluating the PK/PD of traditional and novel beta-lactams in settings potentially involving critically ill OLT recipients. Retrieved evidence were categorized according to the concepts of the so-called "antimicrobial therapy puzzle", specifically assessing a) beta-lactam PK/PD features, with specific regard to aggressive PK/PD target attainment; b) site of infection, with specific regard to beta-lactam penetration in the lung, ascitic fluid, and bile; and c) pathophysiological alterations, focusing mainly on those specifically associated with OLT. Overall, several research gaps still exist in assessing the PK behavior of beta-lactams in critical OLT recipients. The impact of specific OLT-associated pathophysiological alterations on the attainment of optimal PK/PD targets may represent an important field in which further studies are warranted. Assessing the relationship between aggressive beta-lactam PK/PD target attainment and clinical outcome in critical OLT recipients will represent a major challenge in the next future.

References

Shafiekhani M, Mirjalili M, Vazin A . Prevalence, Risk Factors And Treatment Of The Most Common Gram-Negative Bacterial Infections In Liver Transplant Recipients: A Review. Infect Drug Resist. 2020; 12:3485-3495. PMC: 6859291. DOI: 10.2147/IDR.S226217. View

Schneider A, Andre P, Scheier J, Schmidt M, Ziervogel H, Buclin T . Pharmacokinetics of anti-infective agents during CytoSorb hemoadsorption. Sci Rep. 2021; 11(1):10493. PMC: 8131695. DOI: 10.1038/s41598-021-89965-z. View

Antunes M, Teixeira A, Fortuna P, Moya B, Martins A, Bagulho L . Infections After Liver Transplantation: A Retrospective, Single-center Study. Transplant Proc. 2015; 47(4):1019-24. DOI: 10.1016/j.transproceed.2015.03.009. View

Tu Z, Xiang P, Xu X, Zhou L, Zhuang L, Wu J . DCD liver transplant infection: experience from a single centre in China. Int J Clin Pract. 2016; 70 Suppl 185:3-10. DOI: 10.1111/ijcp.12810. View

Weiss E, Dahmani S, Bert F, Janny S, Sommacale D, Dondero F . Early-onset pneumonia after liver transplantation: microbiological findings and therapeutic consequences. Liver Transpl. 2010; 16(10):1178-85. DOI: 10.1002/lt.22132. View

Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P . Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of.... Crit Care. 2019; 23(1):104. PMC: 6441232. DOI: 10.1186/s13054-019-2378-9. View

Hagel S, Bach F, Brenner T, Bracht H, Brinkmann A, Annecke T . Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial. Intensive Care Med. 2022; 48(3):311-321. PMC: 8866359. DOI: 10.1007/s00134-021-06609-6. View

Gatti M, Rinaldi M, Laici C, Siniscalchi A, Viale P, Pea F . Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented.... Antibiotics (Basel). 2023; 12(11). PMC: 10668725. DOI: 10.3390/antibiotics12111599. View

Dupon M, Janvier G, Vincon G, Winnock S, Demotes-Mainard F, Capeyron O . Plasma levels of piperacillin and vancomycin used as prophylaxis in liver transplant patients. Eur J Clin Pharmacol. 1993; 45(6):529-34. DOI: 10.1007/BF00315309. View

10.

Roberts J, Abdul-Aziz M, Lipman J, Mouton J, Vinks A, Felton T . Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014; 14(6):498-509. PMC: 4181663. DOI: 10.1016/S1473-3099(14)70036-2. View

11.

Tam V, Chang K, Zhou J, Ledesma K, Phe K, Gao S . Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria. J Antimicrob Chemother. 2017; 72(5):1421-1428. DOI: 10.1093/jac/dkx001. View

12.

Karapanagiotou A, Kydona C, Papadopoulos S, Giasnetsova T, Sgourou K, Pasakiotou M . Infections after orthotopic liver transplantation in the intensive care unit. Transplant Proc. 2012; 44(9):2748-50. DOI: 10.1016/j.transproceed.2012.09.004. View

13.

Laici C, Gamberini L, Bardi T, Siniscalchi A, Bacchi Reggiani M, Faenza S . Early infections in the intensive care unit after liver transplantation-etiology and risk factors: A single-center experience. Transpl Infect Dis. 2018; 20(2):e12834. DOI: 10.1111/tid.12834. View

14.

Chiriac U, Richter D, Frey O, Rohr A, Helbig S, Preisenberger J . Personalized Piperacillin Dosing for the Critically Ill: A Retrospective Analysis of Clinical Experience with Dosing Software and Therapeutic Drug Monitoring to Optimize Antimicrobial Dosing. Antibiotics (Basel). 2021; 10(6). PMC: 8227218. DOI: 10.3390/antibiotics10060667. View

15.

De Waele J, Carrette S, Carlier M, Stove V, Boelens J, Claeys G . Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med. 2013; 40(3):380-7. DOI: 10.1007/s00134-013-3187-2. View

16.

Giannella M, Rinaldi M, Viale P . Antimicrobial Resistance in Organ Transplant Recipients. Infect Dis Clin North Am. 2023; 37(3):515-537. DOI: 10.1016/j.idc.2023.04.001. View

17.

Lasko M, Serrano O, Kois A, Nicolau D, Kuti J . Effect of Blood Product Resuscitation on the Pharmacokinetics of Ampicillin-Sulbactam during Orthotopic Liver Transplantation. Surg Infect (Larchmt). 2021; 23(2):119-126. DOI: 10.1089/sur.2021.218. View

18.

Abdulla A, Ewoldt T, Purmer I, Muller A, Gommers D, Endeman H . A narrative review of predictors for β-lactam antibiotic exposure during empirical treatment in critically ill patients. Expert Opin Drug Metab Toxicol. 2021; 17(4):359-368. DOI: 10.1080/17425255.2021.1879049. View

19.

Sumi C, Heffernan A, Lipman J, Roberts J, Sime F . What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review. Clin Pharmacokinet. 2019; 58(11):1407-1443. DOI: 10.1007/s40262-019-00791-z. View

20.

Pai Mangalore R, Ashok A, Lee S, Romero L, Peel T, Udy A . Beta-Lactam Antibiotic Therapeutic Drug Monitoring in Critically Ill Patients: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2022; 75(10):1848-1860. PMC: 9662173. DOI: 10.1093/cid/ciac506. View